SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Apnimed, Inc. (APMD) Reports $29.5M Q3 Net Loss; FDA Decision Targeted for Feb. 2027

Apnimed reported a Q3 2026 net loss of $29.5M versus $10.9M in Q3 2025 and approximately $351.8M in cash at Sept. 30, 2026. Its AD109 NDA is under FDA review, with a PDUFA goal date of Feb. 28, 2027.Material DetailsContext by AI AnalystThis is a late-stage regulatory period: Apnimed has completed t…

APMD

Related stories